celecoxib
Country
- ๐ All countries 18
- Afghanistan 0
- Australia 1
- Austria 0
- Belarus 0
- Brazil 0
- Bulgaria 0
- Canada 1
- China 0
- Egypt 0
- Eritrea 0
- European Union 1
- France 2
- Germany 0
- Global (Riot Games sanctioned tournaments) 0
- Greece 0
- Hong Kong 0
- Hungary 0
- India 0
- Iran 0
- Iraq 0
- Italy 0
- Japan 1
- Kuwait 0
- Netherlands 0
- Nigeria 0
- North Korea 0
- Norway 0
- Pakistan 0
- Qatar 0
- Rhodesia (now Zimbabwe) 0
- Russia 0
- Saudi Arabia 0
- Singapore 5
- South Africa 0
- Spain 0
- Thailand 1
- Turkey 0
- Turkmenistan 0
- UAE 1
- UK 2
- USA 3
Category
- All categories 1
- Apps & Websites 0
- Activities & Laws 0
- Books 0
- Products 1
- Food & Drink 0
- Games 0
- Movies & TV 0
- Music 0
- Clothing & Symbols 0
celecoxib
The EU withdrew the marketing authorisation for celecoxib (Onsenal) for familial adenomatous polyposis due to insufficient benefit and increased cardiovascular/GI risk.
- Status
- Restricted
- Country
- European Union
- Category
- Products
- Banned since
- 2011-04
- Last checked
- 21/11/2026
The European Medicines Agency reviewed data on celecoxib for FAP and concluded that the clinical benefit was not demonstrated and risks outweighed benefits.
Consequently, the licence holder voluntarily withdrew the indication in April 2011, and the drug is no longer approved for that use in the EU.
Sources
Frequently Asked Questions
Was celecoxib completely banned in the EU?
No, only the specific indication for reducing intestinal polyps in FAP was withdrawn; celecoxib remains approved for other uses.